The truth about drug innovation

Jun 24, 2008

A new report co-authored by Manhattan Institute senior fellow Benjamin Zycher, and Joseph DiMasi, and Christopher-Paul Milne, researchers from the Tufts Center for the Study of Drug Development, examines case histories for thirty-five important pharmaceutical innovations. Skeptics of the private industry assert that the development of new medicines is most attributable to publicly funded sources.

As Marcia Angell, former editor-in-chief of The New England Journal of Medicine, remarked during an interview with PBS News : "Innovation comes mainly from NIH-supported research in academic medical centers. The drug companies do almost no innovation."

In this new study, the authors debunk this assertion and argue that the private sector plays a critical role in drug development.

Key findings include:

-- NIH-sponsored research tends to be concentrated on the basic science of disease biology, biochemistry, and disease processes, the goal of which is to identify biologic targets that might prove vulnerable to drugs yet to be developed.

-- Private sector contributions are weighted heavily toward the applied science of discovering ways to pursue treatments and cures for adverse medical conditions.

The authors conclude that NIH-sponsored and private-sector drug research are complementary to one another and are equally necessary in order to provide patients with better care and treatment.

Source: Tufts University, Health Sciences

Explore further: First newborn screening test approved for rare immune disorder

add to favorites email to friend print save as pdf

Related Stories

Consumer loyalty driven by aesthetics over functionality

1 hour ago

When designing a new car, manufacturers might try to attract consumers with more horsepower, increased fuel efficiency or a lower price point. But new research from San Francisco State University shows consumers' loyalty ...

Recommended for you

New system targets germs in donated blood plasma

5 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.